# Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

> **NCT02600923** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 131 (actual)

## Conditions studied

- Advanced Breast Cancer Female

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02600923
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-15
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600923, "Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02600923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*